Company Encyclopedia
View More
name
Proshares Smart Materials ETF
TINT.US
News
View More

Merck & Co., Inc. $MRK Shares Purchased by OFI Invest Asset Management

OFI Invest Asset Management increased its stake in Merck & Co., Inc. by 2.5% in Q3, owning 733,819 shares valued at $61.59 million. Other major investors also adjusted their positions, with significant stakes acquired by DLD Asset Management, Norges Bank, and Franklin Resources. Merck's stock opened at $104.79, with a market cap of $260.08 billion. The company announced a quarterly dividend increase to $0.85 per share.

Market Beat·
US
MRK
0.00%
Market Beat·
US
MRK
0.00%

Applied Materials Inc. Stock Outperforms Competitors On Strong Trading Day

Applied Materials Inc. (AMAT) shares rose 1.01% to $259.01, outperforming competitors on a strong trading day. The S&P 500 and Dow Jones also saw gains. This marks the third consecutive day of gains for AMAT, which is 6.19% below its 52-week high. Trading volume was below the 50-day average.

Dow Jones·
US
AMAT
0.00%
Dow Jones·
US
AMAT
0.00%

Smart Money Is Betting Big In AMAT Options

Whales are showing a bearish stance on Applied Materials (AMAT) with significant options trades. 58% of investors have bearish expectations, targeting a price range of $180 to $310. Analysts have varied ratings, with UBS upgrading to Buy and Jefferies maintaining a Buy rating with a target of $360. The stock is currently up 1.22% at $259.55, with RSI indicators suggesting it may be overbought. Next earnings are expected in 52 days.

benzinga_article·
US
AMAT
0.00%
benzinga_article·
US
AMAT
0.00%

What Merck (MRK)'s Diabetes Price Cuts and Oncology Advances Mean For Shareholders

Merck has agreed to significantly reduce U.S. prices for diabetes drugs, including JANUVIA, JANUMET, and JANUMET XR, through a direct-to-patient program. Additionally, Merck reported positive Phase 3 results for KEYTRUDA plus Padcev in bladder cancer, enhancing its oncology portfolio. These moves aim to balance affordability pressures with investment in high-impact therapies. Merck's narrative projects $72 billion revenue and $24.3 billion earnings by 2028, requiring 4.2% yearly growth. The company faces risks from KEYTRUDA patent pressure and broader pricing impacts on margins.

Simplywall·
US
MRK
0.00%
Simplywall·
US
MRK
0.00%

Dow's Nearly 125-Point Rally Led By Gains In Chevron, Merck Shares

The Dow Jones Industrial Average rose by nearly 125 points, driven by gains in Chevron and Merck shares. Chevron's shares increased by $2.61 (1.8%), and Merck's by $1.57 (1.6%), contributing approximately 26 points to the Dow's rise. Other significant contributors included NVIDIA, JPMorgan Chase, and Caterpillar. A $1 move in any Dow component results in a 6.16-point swing. Data was compiled on December 22, 2025.

Dow Jones·
US
MRK
0.00%
US
CVX
0.00%
Dow Jones·
US
MRK
0.00%
US
CVX
0.00%
© 2025 Longbridge｜Disclaimer